Please login to the form below

Not currently logged in
Email:
Password:

Elan promotes president of R&D to board

Irish biotech Elan has hired Dr Lars Ekman, who is currently president of R&D, to the position of member of the operating committee and the board of directors

Irish biotech Elan has hired Dr Lars Ekman, who is currently president of R&D, to the position of member of the operating committee and the board of directors.

Dr Ekman will transition from his current operational role to become an advisor as a member of the board of directors from 31 December 2007. He will continue to chair the science and technology committee on matters relating to Elan's research platform and portfolio. Other board members include Dr Dennis Selkoe and Dr Floyd Bloom.

Ekman will remain an integral part of the company's science, clinical development and corporate activities and will continue as key senior spokesperson for Elan as president of R&D. He will also continue as co-chair on the joint steering committee with US-based pharmaceutical company Wyeth. Ekman's responsibility will be to focus on Elan's intermediate and long-term plans as he dedicates his time to provide strategic advice to the chairman and the CEO in his continuing role as a member of the board of directors.

Ekman joined Elan in January 2001 after holding a number of senior executive positions in the pharmaceutical industry. During this period, Elan received approval for four US NDAs, three EU marketing approval applications and five iNDAs. His efforts have seen the drugs Prialt and Tysabri come to market and progressing further several of Elan's Alzheimer's immunotherapy programmes.

9th August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...